Christian Kurbacher is commenting on the poster: P5-14-22 Qt-interval prolongation during the treatment with ribociclib and endocrine agents in patients with hormone receptor-positive, human epidermal growth factor 2-negative metastatic breast cancer: A real-world experience
Patrick Neven is commenting on the poster: PD2-08 Gene expression analysis and association with treatment response in postmenopausal patients with hormone receptor-positive, HER2-negative advanced breast cancer in the MONALEESA-3 study
Rachel Layman is commenting on the poster: PD7-09 A phase 1/1b study of LSZ102, an oral selective estrogen receptor degrader (SERD), in combination with ribociclib in patients with estrogen receptor-positive (ER+) advanced breast cancer (ABC) who had progressed after endocrine therapy (ET)
Francois Duhoux is commenting on the abstract: PD7-09 A phase 1/1b study of LSZ102, an oral selective estrogen receptor degrader (SERD), in combination with ribociclib in patients with estrogen receptor-positive (ER+) advanced breast cancer (ABC) who had progressed after endocrine therapy (ET)
Claudio Zamagni is commenting on the poster: P1-19-21 Ribociclib + letrozole in patients with HR+, HER2− advanced breast cancer: Safety analysis of the phase 3b CompLEEment-1 trial
JoaquiÌn Gavilá is commenting on the abstract: GS2-05 Primary results of SOLTI-1402/CORALLEEN phase 2 trial of neoadjuvant ribociclib plus letrozole versus chemotherapy in PAM50 Luminal B early breast cancer: An open-label, multicenter, two-arm, randomized study
